Treatment of Axial Spondyloarthritis: What Does the Future Hold?

[1] Rudwaleit M(2009)The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection Ann Rheum Dis 68 777-783

[2] van der Heijde D(2011)Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis Ann Rheum Dis 70 1369-1374

[3] Landewe R(2013)Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum 65 543-551

[4] Listing J(2017)Axial spondyloarthritis Lancet. 390 73-84

[5] Akkoc N(2017)2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis Ann Rheum Dis 76 978-991

[6] Brandt J(2019)2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis Arthritis Care Res (Hoboken) 71 1285-1299

[7] Braun J(2006)Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis J Rheumatol 33 1805-1812

[8] Chou CT(2008)Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study Ann Rheum Dis 67 323-329

[9] Collantes-Estevez E(2016)Brief report: course of active inflammatory and fatty lesions in patients with early axial Spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: results from the infliximab as first line therapy in patients with early active axial Spondyloarthritis trial Arthritis Rheum 68 1899-1903

[10] Dougados M(2014)Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 Ann Rheum Dis 73 101-107

[1] Rudwaleit M(2009)The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection Ann Rheum Dis 68 777-783

[2] van der Heijde D(2011)Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis Ann Rheum Dis 70 1369-1374

[3] Landewe R(2013)Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum 65 543-551

[4] Listing J(2017)Axial spondyloarthritis Lancet. 390 73-84

[5] Akkoc N(2017)2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis Ann Rheum Dis 76 978-991

[6] Brandt J(2019)2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis Arthritis Care Res (Hoboken) 71 1285-1299

[7] Braun J(2006)Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis J Rheumatol 33 1805-1812

[8] Chou CT(2008)Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study Ann Rheum Dis 67 323-329

[9] Collantes-Estevez E(2016)Brief report: course of active inflammatory and fatty lesions in patients with early axial Spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: results from the infliximab as first line therapy in patients with early active axial Spondyloarthritis trial Arthritis Rheum 68 1899-1903

[10] Dougados M(2014)Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 Ann Rheum Dis 73 101-107